News | March 06, 2014

TAVR Implant Count Reaches 100 at Birmingham Hospital

TAVR Heart valve repair Hybrid OR Edwards Lifesciences Sapien

March 6, 2014 — At age 88, Lena M. Smith visited her doctor, Larry Hunt, M.D., at the University of Alabama at Birmingham to find out why her energy level had diminished. 

Hunt, a primary care physician and assistant professor in the UAB School of Medicine, detected a heart murmur, and an echocardiogram confirmed aortic stenosis. Smith needed her aortic valve replaced. UAB Heart and Vascular Services cardiothoracic surgeon Spencer Melby, M.D., and interventional cardiologist Seun Alli, M.D., scheduled Smith for the minimally invasive Edwards Lifesciences Sapien transcatheter heart valve replacement system surgery. She became the 100th patient to undergo the procedure at UAB Hospital since the program began in August 2012.   

 “I feel great — amazing,” Smith said. “I’m a satisfied customer and ready to get moving again.” 

UAB is home to Alabama’s largest and oldest heart valve disease treatment program and is one of just a few in the state trained to offer the Edwards Lifesciences TAVR — the only transcatheter aortic valve replacement therapy approved for commercial use in the United States. UAB performs more valve procedures annually than anyone in the state and has since the inception of its program. 

UAB completed its 100th TAVR transplant in 18 months. Many programs around the country complete approximately 50 TAVR procedures in the same time period. 

“We have had great success since we began doing the TAVR procedure, and a big reason for that is that we have a tremendous team in place,” Alli said. “In many cases, these are really sick people who don’t have a lot of other options. Open-heart surgeries just aren’t possible because of the age or other medical issues of the patient in most cases. But we’ve done 100 of these cases with minimum complications, and we’ve had very good outcomes. We’ve seen that when they come back to clinic for follow-up they are symptomatically better and have an improved quality of life. 

The big advantage to the TAVR procedure is that surgeons can replace valves without open-heart surgery. 

For more information: www.uab.edu


Related Content

News | Heart Valve Technology

May 27, 2025 — Abbott has announced the U.S. Food and Drug Administration (FDA) has approved the company's Tendyne ...

Home May 28, 2025
Home
News | Heart Valve Technology

May 2, 2025 – New analysis from the EARLY TAVR trial showed patients between the age of 65 and 70 years old derived the ...

Home May 02, 2025
Home
News | Heart Valve Technology

April 28, 2025 — The Society of Thoracic Surgeons (STS) has launched its latest surgical risk calculator designed for ...

Home April 29, 2025
Home
News | Heart Valve Technology

March 30, 2025 — Medtronic has announced late-breaking data on five-year outcomes from the Evolut Low Risk Trial. Data ...

Home March 31, 2025
Home
News | Heart Valve Technology

Feb. 22, 2025 — More than 60,000 people die from heart valve disease (HVD) in the U.S. each year, according to the ...

Home March 04, 2025
Home
News | Heart Valve Technology

Feb. 17, 2025 — The International Consortium for Health Outcomes Measurement (ICHOM) has developed a globally inclusive ...

Home February 18, 2025
Home
News | Heart Valve Technology

Feb. 13, 2025 — Research from Cedars-Sinai investigators and collaborators at other leading medical institutions is ...

Home February 18, 2025
Home
News | Heart Valve Technology

Jan. 25, 2025—A new study presented at the 2025 Society of Thoracic Surgeons (STS) Annual Meeting reveals that ...

Home January 27, 2025
Home
News | Heart Valve Technology

Jan. 6, 2025 — Medtronic plc has announced it received CE (Conformité Européenne) Mark for the Harmony Transcatheter ...

Home January 06, 2025
Home
News | Heart Valve Technology

Sept. 1, 2024 — Researchers at UTHealth Houston have identified genetic variants linked to a rare form of bicuspid ...

Home September 04, 2024
Home
Subscribe Now